BNET Industries
Market Cap:$93.2B
Last Fiscal Year Sales:$32.4B
- Public
- CH
Dow Jones Description
Roche's focus is health. Roche Holding Ltd. (OTC: RHHVF (ADR) Swiss) was founded in 1896 and is headquartered in Basel, Switzerland. The company operates in two segments, which are pharmaceuticals and diagnostics. Its drugs include Accutane, Herceptin, Invirase, Rituxan, Rocephin, Tamiflu, and Xenical, among others. It owns 60% of Genentech and 51% of Chugai Pharmaceutical. The company has annual revenue of about $27 billion and employs about 68,000 people. In 2005, it sold its consumer healthcare division to Bayer, allowing it to focus on core business.In July 2005 the company acquired GlycArt Biotechnology AG, a privately owned Swiss biotech company that provides technology for enhancing the efficacy of antibodies will further strengthen Roche's expertise in therapeutic antibody research and development.
Chief Executive OfficerSeverin Schwan
Number of Employees 80,080
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
Covagen announces collaboration with Roche
-
Biogen says panel backs Genentech partnership
-
Raptor Pharmaceuticals announces licensing agreement with Roche Holding for NeuroTransTM
-
Roche teams with Pontifax on Israeli investments: The deal could be worth tens of millions...
-
Roche Downplays Avastin Failure, Defends Genentech Deal Value
-
Tom Marsico Is Pound-the-Table Bullish
-
Drug firms eye deals to maintain growth
-
Roche teams with Spanish Lung Cancer Group to investigate Tarceva in lung cancer patients
-
(4/15) Roche's Pascal Soriot to lead Genentech
-
Roche says Genentech CEO will chair Genentech's new board
-
SmarTrendR News Watch: Roche Says Genentech CEO Will Remain With The Company
-
Pharma needs biotech for growth
-
UPDATE 3-Roche says Genentech's Levinson to stay on board
News & Analysis
Filter by
roche holding ag - All News and Analysis
Roche's Accutane: Suit Over Death of Congressman's Son Nixed
BNET
- 2009-06-11
Roche has won a ruling insulating it from allegations that its Accutane acne drug caused the suicide of U.S. Rep. Bart Stupak's son. B.J. Stupak started taking Accutane in 1999. In May 2000, at age 17, he shot himself in the head. by Jim Edwards
With Avastin Effectiveness Questioned, Roche's Acquisition of Genentech Looks Hasty
BNET
- 2009-06-03
The news for Roche on Avastin gets worse: Forbes' Matt Herper just published a lengthy piece which suggests, in layman's terms, that the $4.8 billion cancer drug kinda doesn't work very well. by Jim Edwards
Coda: How To Build A Cloud Company
BNET
- 2009-05-01
Software vendors are coming under increasing pressure to offer customers software hosted in the cloud as an alternative to the software license agreements that have characterized the software industry for more than twenty years. Once confined to the ghetto of small-bore applications that...
ImmunoGen, Inc. F3Q09 (Quarter End 03/31/09) Earnings Call Transcript
Seeking Alpha
- 2009-04-30
Question-and-Answer SessionOperator Operator Instructions Your first question comes from Joel Sendek with Lazard Capital Markets. Joel Sendek - Lazard Capital Markets Given the fact that the agiment data for colon for Avastin didn’t work and you have a program moving forward with DM1 and agiment breast,...
Roche Q1: How Genentech Might Hurt Roche's Sales and Management Productivity
BNET
- 2009-04-21
One counter-intutive question here is whether Roche's acquisition of Genentech will hurt Roche more than it hurts Genentech. by Jim Edwards
Dorfman: SEC Launched Insider Trading Probe on Pfizer-Wyeth, Merck-Schering and Roche-Genentech
BNET
- 2009-04-09
The Huffington Post's Dan Dorfman reports that the SEC and FINRA another finance regulatory body have launched insider trading probes to figure out whether stock was improperly traded ahead of the wave of recent mergers in pharmaceuticals. Among the deals under scrutiny are Pfizer's acquisition of Wyeth,...
Roche Has Upper Hand in Battle for Genentech R&D Talent
BNET
- 2009-03-17
Everyone thinks that the Roche-Genentech merger will destroy Genentech's "culture," either because the stuffy suits from Roche will crimp the grass-skirt-and-coconut-bra vibe at Genentech or because Genentech scientists will look at all the money they just made on their stock and leave. If that happens, all their knowledge -- and...
Halozyme Therapeutics, Inc. Q4 2008 Earnings Call Transcript
Seeking Alpha
- 2009-03-13
Question-and-Answer SessionOperator And the first question comes from Kevin DeGeeter. Kevin DeGeeter Hi, good morning, guys. Jonathan Lim Hi, good morning. Kevin DeGeeter A couple of quick questions here. For the glucodynamic study and inter-patient variability study for insulin, should we eventually look for those being presented? Is that...
Roche-Genentech Takeover Will Cost 1,500 Jobs in N.J.; Roche Name to Go
BNET
- 2009-03-13
The Roche takeover of Genentech will cost 1,500 jobs in New Jersey as sales and marketing positions are axed there. R&D staff look more secure, according to the Star-Ledger. The company will also change its name to Genentech. The move makes a mockery of a press conference...
Genentech's Levinson May Have No Change-of-Control Agreement in Roche Deal
BNET
- 2009-03-12
Genentech CEO Arthur Levinson gets no special benefits for agreeing to sell his company to Roche for $95 a share, according to the company's most recently filed proxy statement. That's a stark contrast to Schering-Plough CEO Fred Hassan, who had specific cash bonuses written into his compensation...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Severin Schwan | Chief Executive Officer |
| William M. Burns | CEO, Roche Pharma |
| Erich Hunziker | CFO |
| Jonathan K.C. Knowles | Managing Director, Global Pharmaceutical Research |
| Roche Rolf D Schl | Managing Director, Partner |
| Rolf D Schl | Managing Director, Partner |
| Andres Greuter | Compliance Officer |
| Gottlieb A. Keller | Secretary & Head, Corp Services, HR |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Dr Roche Gottlieb Keller | Chairman |
| Andre Hoffman | Board of Directors |
| Andre Hoffmann | Vice-Chairman of the Board |
| Andreas Oeri | Board of Directors |
| Brouno Gehring | Vice Chairman |
| Bruno Gehrig | Vice Chairman |
| DeAnne S. Julius | Board of Directors |
| F Hoffmann | Vice chairman |
| Horst Teltschik | Board of Directors |
| John Irving Bell | Board of Directors |
| Lodewijk J.R. De Vink | Board of Directors |
| Peter Brabeck-Letmathe | Board of Directors |
| Roche Rolf H A nggi | Vice-Chairman |
| Rolf Haenggi | Board of Directors |
| Rolf Hanggi | Board of Directors |
| Walter Frey | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Chief Executive Officer | Current |
| University of Innsbruck | Degree, Economics | Former |
| University of Innsbruck | Doctorate in Law | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | CEO, Roche Pharma | Current |
| Roche Products (Proprietary) Limited | President | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | CFO | Current |
| F. Hoffmann-La Roche Ltd. | CFO | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| Genentech, Inc. | Board of Directors | Current |
| Holcim Ltd. | Board of Directors | Current |
| Diethelm Keller Holding Ltd. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Global Pharmaceutical Research | Current |
| Genentech, Inc. | Head, Global Research | Current |
| Genentech, Inc. | Board of Directors | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| University of East Anglia | Honours Degree in Molecular Genetics | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Partner | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Partner | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Compliance Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Diagnostics Corporation | Secretary | Current |
| Roche Holding Ltd. | Secretary & Head, Corp Services, HR | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Diagnostics Corporation | Secretary | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Living Planet Management Company | Chairman | Current |
| Roche Holding Ltd. | Vice-Chairman of the Board | Current |
| Roche Holding Ltd. | Member | Current |
| Nestle Uk Ltd | Brand Manager | Former |
| INSEAD | Masters of Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| University of Basel | Medical Studies | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice Chairman | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| University of Bern | Doctorate in economics (Dr | Former |
| Organization | Position | Status |
|---|---|---|
| The Royal Institute of International Affairs | Chairman | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| BP plc | Board of Directors | Current |
| University of California | Ph.D In Economics | Former |
| Iowa State University | Ph.D | Former |
| Iowa State University | Bsc | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice chairman | Current |
| Roche Holding Ltd. | Chief Executive Officer | Former |
| Diageo plc | Board member | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
Peter Brabeck-Letmathe has been a member of the Board since 1997 and served as Vice-Chairman from 2000 to 2005 and since 2008. Since 2008 he has also served on the Chairman's and Governance Committee and the Compensation Committee. On both of these committees he has already served in the past, namely from 2003 to 2005 and 2000 to 2005, respectively. His term as a member of the Board expires at the AGM in 2011. The Board has determined him to be independent under the Group’s independence standards. Peter Brabeck-Letmathe studied Economics at the University of World Trade in Vienna. After graduation in 1968, he joined Nestlé’s sales operations in Austria. His career at Nestlé includes a variety of assignments in several European countries as well as in Latin America. Since 1987, he has been based at Nestlé’s headquarters in Vevey. Since 1997, Mr. Brabeck-Letmathe has served as the Chief Executive Officer of Nestlé and as a member of Nestlé’s Board of Directors. In 2005, Mr. Brabeck-Letmathe was appointed Chairman of the Board of Directors of Nestlé. As of April 10, 2008 he has retired from his function as Chief Executive Officer of Nestlé. Mr. Brabeck is a member of the Boards of Directors of L’Oréal SA, Paris (since 1997) and Roche Holding SA, Basel (since 2000). He is also a member of the Foundation Board of the World Economic Forum and a member of the European Round Table of Industrialists.
| Organization | Position | Status |
|---|---|---|
| Credit Suisse Group | Vice Chairman | Current |
| Winterthur Schweizerische Versicherungs Gesellschaft | Vice Chairman | Current |
| Credit Suisse Group | Board of Directors | Current |
| Nestle S.A. | Board of Directors | Current |
| L'Oreal S.A. | Board of Directors | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| World Economic Forum | Member, Foundation Board | Current |
| Nestle S.A. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice-Chairman | Current |
| Zurich Insurance Company | Deputy Chief Executive Officer | Former |
| Zurich Insurance | Member | Former |
| Zurich Insurance Company | Member | Former |
| Nestle S.A. | Vice-Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Holding Ltd. | Vice Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Nestle S.A. | Second Vice Chairman | Current |
| Nestle S.A. | Second Vice Chairman | Current |
| Zurich Insurance Company | Deputy Chief Executive Officer | Former |
| Zurich Insurance Company | Member | Former |
| Zurich Insurance | Member | Former |
| Nestle S.A. | Vice-Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
Executive News
-
BP Selects New Chairman
-
BP: BP Selects New Chairman to Succeed Peter Sutherland
-
KineMed to Collaborate with Bristol-Myers Squibb
-
Cancer Drugs: Herceptin News and More
-
Cancer Drugs: News from ASCO
| Volume | 210,369 |
| Shares Outstanding | 2.8B |
| Market Cap | 93.2B |
| Year High | 46.70 |
| Year Low | 26.010 |
| Earnings Per Share | 2.37 |
| P/E Ratio | 14.0042 |
| Dividend | 0.6652 |
| Yield | 2.0042 |
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
